Loading...
•
Sep 30, 2025
BillionToOne, Inc. Q3 2025 Earnings Report
BillionToOne reported strong Q3 2025 results, achieving profitability and revenue growth driven by increased test volumes and improved gross margin.
Key Takeaways
BillionToOne achieved profitability in Q3 2025 with $83.5M in revenue, $1.5M in net income, and $9.6M in operating income, supported by strong growth in prenatal and oncology testing.
Total revenue reached $83.5M, more than doubling from the previous year.
Net income turned positive at $1.5M compared to a loss in Q3 2024.
Gross margin improved significantly to 70%.
Test volumes and ASPs increased across both prenatal and oncology segments.
Revenue by Segment
Forward Guidance
BillionToOne expects strong Q4 2025 performance with continued revenue growth and positive operating income for both Q4 and full-year 2025.
Positive Outlook
- Q4 2025 revenue expected to be $84M to $90M
- Full-year 2025 revenue guidance of $293M to $299M
- Positive GAAP operating income expected in Q4
- Positive GAAP operating income expected for full-year 2025
- Continued strength across both prenatal and oncology segments
Challenges Ahead
- Non-GAAP EPS not provided
- No geographic revenue segmentation disclosed
- Significant increase in operating expenses YoY
- No specific R&D updates or pipeline developments mentioned
- IPO proceeds not linked to specific growth initiatives
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...